Norberto Perico, Giuseppe Remuzzi, Matthew D Griffin, Paul Cockwell, Alexander P Maxwell, Federica Casiraghi, Nadia Rubis, Tobia Peracchi, Alessandro Villa, Marta Todeschini, Fabiola Carrara, Bernadette A Magee, Piero L Ruggenenti, Stefano Rota, Laura Cappelletti, Veronica McInerney, Tomás P Griffin, Md Nahidul Islam, Martino Introna, Olga Pedrini, Josée Golay, Andrew A Finnerty, Jon Smythe, Willem E Fibbe, Stephen J Elliman, Timothy O'Brien
BACKGROUND: Systemic therapy with mesenchymal stromal cells (MSCs) may target maladaptive processes involved in diabetic kidney disease (DKD) progression. However, clinical translation of this approach has been limited. METHODS: The Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM) study, a randomized, placebo-controlled phase 1b/2a trial, assesses safety, tolerability, and preliminary efficacy of next-generation bone marrow-derived, anti-CD362-selected, allogeneic MSCs (ORBCEL-M) in adults with type 2 diabetes and progressive DKD...
August 10, 2023: Journal of the American Society of Nephrology: JASN